Eye :: NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases

Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for “New Models for Eye Diseases” will support the Phylonix program over a period of three years.

Glaucoma :: Glaucoma surgery in the blink of an eye

Prof. Ehud Assia, of Tel Aviv University?s Sackler School of Medicine is, quite simply, a rock star in the field of eye surgery. One of a small number of surgeons in the world who currently perform a complicated form of glaucoma surgery, Prof. Assia has developed a novel laser device that promises to revolutionize treatment of the disease.

Glaucoma :: Alzheimer’s disease treatments may help treat major eye disease glaucoma

UK scientists have shown for the first time that key proteins involved in Alzheimer’s disease are also implicated in glaucoma, the major cause of irreversible blindness worldwide. Research carried out at the UCL Institute of Ophthalmology and funded by the Wellcome Trust has also shown that novel drugs being trialled for Alzheimer’s disease which target this protein may be used to treat glaucoma.

Glaucoma :: New treatment for glaucoma shows promise in laboratory

Iowa State University researchers have developed a new technique that successfully treated rats for blindness caused by glaucoma. Their experimental treatment will be used on canine patients in the next year. If successful, it is expected to move to human trials.

Do NOT follow this link or you will be banned from the site!